GlassScriptPhysician profile
Christopher Charles Copenhaver
NPI 1659370708
$88,153.41
in general payments reported to CMS, 2019-2025
34 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $6,945 · 2021: $11K · 2022: $18K · 2023: $27K · 2024: $20K · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $8,100 · Consulting Fee: $3,957 · Honoraria: $350 · Travel and Lodging: $300 · Education: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,725.00 |
| Food and Beverage | $8,099.84 |
| Consulting Fee | $3,956.56 |
| Honoraria | $350.00 |
| Travel and Lodging | $299.71 |
| Education | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39,717.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $32,096.84 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $7,645.39 | 2019-2025 | |
| Genzyme Corporation | $1,457.62 | 2019-2025 | |
| Csl Behring | $1,031.38 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $786.83 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $749.08 | 2019-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $550.91 | 2022-2024 | |
| Amgen INC. | $498.04 | 2022-2025 | Tezspire |
| Pfizer INC. | $488.90 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $432.79 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $413.97 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $305.17 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $298.55 | 2025 | Neffy |
| Pharming Healthcare, INC. | $281.16 | 2019-2025 | Ruconest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $194.57 | 2020-2024 | |
| Alk-Abello, INC | $191.27 | 2019-2021 | |
| Kaleo, INC. | $155.82 | 2019-2023 | Auvi-Q |
| Sanofi US Services INC. | $135.00 | 2025 | |
| Optinose US, INC. | $133.95 | 2019-2025 | |
| Blueprint Medicines Corporation | $98.44 | 2023 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $95.72 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.89 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $74.69 | 2021 | |
| Horizon Therapeutics Plc | $50.97 | 2019 | |
| Adma Biomanufacturing LLC | $37.81 | 2024 | |
| Covis Pharma Gmbh | $25.68 | 2022 | |
| Insmed, INC. | $24.70 | 2025 | Arikayce |
| Cycle Pharmaceuticals INC | $20.40 | 2025 | Sajazir |
| Organon LLC | $19.75 | 2025 | |
| Shire North American Group INC | $18.17 | 2019 | |
| Merck Sharp & Dohme LLC | $15.05 | 2023 | |
| Octapharma USA, INC. | $14.77 | 2021 | |
| Mylan Specialty L.P. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Copenhaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.